What is 3,4-dichloromethylphenidate?
|CAS Number||210776-65-1 (racemic)|
|CompTox Dashboard (EPA)||DTXSID30658831|
|Chemical and physical data|
|Molar mass||302.20 g·mol−1|
3,4-Dichloromethylphenidate, often referred to as 3,4-DCMP, is a synthetic chemical compound with stimulant properties. It belongs to the class of substituted phenolates and is structurally related to methylphenidate, a commonly prescribed medication for attention deficit hyperactivity disorder (ADHD). 3,4-DCMP is a research chemical and is not approved for medical use.
- Stimulant Properties: Like methylphenidate, 3,4-dichloromethylphenidate is known for its stimulating effects on the central nervous system. Users may experience increased alertness, wakefulness, and improved focus when under its influence.
- Euphoria: Some individuals have reported feelings of joy while using 3,4-DCMP. This mood-enhancing effect can be appealing but may also contribute to its potential for misuse.
- Increased Energy: Stimulants like 3,4-DCMP can lead to increased energy levels, making it useful for situations requiring sustained attention and mental alertness.
The appropriate dosage of 3,4-dichloromethylphenidate can vary based on individual factors, including tolerance and body weight. However, it is crucial to approach this substance with caution due to its limited research and safety data. Starting with the smallest effective dose is recommended to minimize potential risks. Due to its status as a research chemical, there are no established standard doses.
The safety profile of 3,4-Dichloromethylphenidate is not well understood, primarily due to the lack of comprehensive research and documentation. Some potential concerns related to its use include:
- Cardiovascular Effects: Stimulants like 3,4-DCMP can lead to increased heart rate and elevated blood pressure, potentially posing risks to individuals with pre-existing heart conditions.
- Psychological Effects: Long-term or excessive use of stimulants may lead to psychological issues, including anxiety, paranoia, and addiction.
- Limited Research: The absence of comprehensive research on 3,4-DCMP makes it challenging to assess its long-term safety accurately.
The legal status of 3,4-dichloromethylphenidate varies by country and region. In many areas, it is not approved for medical use and is often classified as a research chemical. Due to its stimulant properties and potential for misuse, it may be subject to regulations or restrictions.
3,4-Dichloromethylphenidate is believed to work similarly to methylphenidate by blocking the reuptake of neurotransmitters like dopamine and norepinephrine in the brain. This action leads to increased levels of these neurotransmitters, resulting in heightened alertness and improved focus. However, further research is needed to understand its pharmacological mechanisms and potential risks fully.
The chemical structure of 3,4-dichloromethylphenidate includes a phenethylamine core with chlorine substitutions at the 3 and 4 positions. This structural composition is characteristic of substituted phenolates, a class of compounds related to methylphenidate and used for their stimulating effects.
3,4-Dichloromethylphenidate, or 3,4-DCMP, is a synthetic compound with stimulant properties similar to methylphenidate. While it has potential benefits such as increased alertness, wakefulness, and improved focus, it is essential to approach it with caution.
The limited research on 3,4-DCMP, combined with concerns about its safety and potential adverse effects, highlights the need for responsible use. Users should exercise restraint when it comes to dosage, consult with healthcare professionals, and stay informed about the legal status of 3,4-Dichloromethylphenidate in their area. Additionally, further scientific investigation is necessary to gain a more comprehensive understanding of its pharmacology and long-term safety implications. As with any substance, prioritizing health and safety should be paramount.
1. What is 3,4-Dichloromethylphenidate (3,4-DCMP)?
3,4-Dichloromethylphenidate (3,4-DCMP) is a synthetic chemical compound with stimulant properties. It is structurally related to methylphenidate, a medication commonly used to treat attention deficit hyperactivity disorder (ADHD).
2. What are the potential effects of 3,4-DCMP?
The potential effects of 3,4-DCMP include increased alertness, wakefulness, improved focus, euphoria, and increased energy levels. It is considered a central nervous system stimulant.
3. Is 3,4-DCMP safe to use?
The safety of 3,4-DCMP is not well understood due to limited research and documentation. As with many stimulants, there may be potential risks associated with its use, including cardiovascular effects and psychological issues.
4. What is the recommended dosage of 3,4-DCMP?
There are no established standard doses for 3,4-DCMP due to its status as a research chemical. It is crucial to approach this substance with caution, starting with the smallest adequate amount to minimize potential risks.
5. Are there any potential side effects of 3,4-DCMP?
Potential side effects of 3,4-DCMP may include increased heart rate, elevated blood pressure, anxiety, paranoia, and possible addiction. Individual responses can vary, and long-term or excessive use may lead to more severe psychological issues.
6. What is the legal status of 3,4-DCMP?
The legal status of 3,4-DCMP varies by country and region. In many areas, it is not approved for medical use and is often classified as a research chemical. Due to its stimulant properties and potential for misuse, it may be subject to regulations or restrictions.
7. How does 3,4-DCMP work in the body?
3,4-DCMP is believed to work similarly to methylphenidate by blocking the reuptake of neurotransmitters like dopamine and norepinephrine in the brain. This action leads to increased levels of these neurotransmitters, resulting in heightened alertness and improved focus. However, further research is needed to understand its pharmacological mechanisms and potential risks fully.
8. Can 3,4-DCMP be taken with other supplements or medications?
The potential interactions between 3,4-DCMP and other supplements or medications need to be well-documented. It is advisable to consult with a healthcare professional before combining 3,4-DCMP with other substances to avoid potential adverse effects or interactions.
9. Should I consult a healthcare professional before using 3,4-DCMP?
Yes, it is strongly recommended to consult with a healthcare professional before using 3,4-DCMP or any research chemical. They can assess your health, guide safe usage, and help you make informed decisions regarding its potential benefits and risks.
10. What alternatives are available to 3,4-DCMP for enhancing alertness and focus?
There are various alternatives to 3,4-DCMP for enhancing alertness and focus, including caffeine, natural nootropics, adequate sleep, and stress management techniques. Consulting with a healthcare professional can help you explore safe and effective options tailored to your needs while prioritizing your health and well-being.
- Legal Highs Under Scrutiny: In a bid to address the rising concerns surrounding legal highs or new psychoactive substances (NPS), a “Temporary Class Drug Order” was implemented. This move aimed to burst the bubble of these emerging substances, which often posed significant health risks. The development was documented in a Criminal Law Blog by Kingsley Napley on April 10, 2015.
- Structure-Activity Relationship Studies: A study conducted in March 1996 delved into the synthesis and pharmacology of potential cocaine antagonists, specifically focusing on methylphenidate analogs. This research, published in the “Journal of Medicinal Chemistry,” explored the structural-activity relationship of aromatic ring-substituted methylphenidate analogs. The study aimed to understand how various modifications to the chemical structure of these analogs affected their pharmacological properties.
- Examining Amphetamine Antagonists: In March 1999, another study delved into the effects of methylphenidate analogs on phenethylamine substrates for the striatal dopamine transporter. This research, documented in the “Journal of Neurochemistry,” explored the potential of these analogs as amphetamine antagonists. Understanding how these compounds interacted with substrates for the dopamine transporter shed light on their potential pharmacological properties.
- Characterizing Novel Methylphenidate Analogs: In May 2002, a study conducted biochemical and behavioral characterization of novel methylphenidate analogs. Published in “The Journal of Pharmacology and Experimental Therapeutics,” this research aimed to provide insights into the properties and effects of these novel compounds, potentially paving the way for the development of new medications or treatments.
- Synthesis and Binding Affinities: In April 2004, a study focused on the synthesis of methylphenidate analogs and their binding affinities at dopamine and serotonin transport sites. Published in “Bioorganic & Medicinal Chemistry Letters,” this research explored the chemical synthesis of these compounds and their interactions with key neurotransmitter transport sites, shedding light on their potential pharmacological effects.
- Restricted Rotation Analogues: A study conducted in May 2007 centered on the synthesis and pharmacology of site-specific cocaine abuse treatment agents. The research focused on restricted rotation analogs of methylphenidate, aiming to develop compounds that could be used to treat cocaine abuse more effectively. This study was documented in the “Journal of Medicinal Chemistry.”
- Chinese Regulatory Measures: In September 2015, China’s Food and Drug Administration issued a notice regarding the “Measures for the Supervision and Administration of Non-Medicinal Narcotic Drugs and Psychotropic Drugs.” This measure aimed to regulate and control non-medicinal narcotic drugs and psychotropic drugs in the country. The notice emphasized the importance of monitoring and managing these substances to ensure public safety.
- Review of Methylphenidate-Based NPS: On March 31, 2015, the Advisory Council on the Misuse of Drugs conducted a review of the evidence regarding the use and harm of methylphenidate-based new psychoactive substances (NPS). This review aimed to assess the risks associated with these substances and provide evidence-based recommendations for regulatory measures.
- Classification of Cannabinoids: In a significant move, cannabinoids were proposed to be classified as health-hazardous goods. This development, documented in Swedish news, marked a potential shift in the legal status of cannabinoids, reflecting growing concerns about their health effects.